Last Updated: 2026

Collegium Pharmaceutical

Rank#5923

Market Cap1.11B

CountryUnited States

Summary

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ER for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.

History

Collegium was founded in 2003 and is headquartered in Canton, Massachusetts. In 2012, Collegium completed a strategic partnership agreement with Covidien, now Mallinckrodt plc, to co-promote Xtampza® ER in the US. Xtampza ER is an oxycodone product utilizing Collegium’s patented DETERx oral abuse deterrent technology.

Mission

Our mission is to provide innovative solutions to address unmet medical needs. We will pursue innovative solutions to meet healthcare need, remain focused on the success of the patient, and sustain excellence in the development of medications.

Vision

Our vision is to become a leader in the development and commercialization of products by utilizing our proprietary DETERx platform technology.

References

https://en.wikipedia.org/wiki/Collegium_International

https://in.investing.com/equities/collegium-pharmaceutical

https://www.comparably.com/companies/vision/mission

https://www.crunchbase.com/organization/collegium-pharmaceutical

https://finance.yahoo.com/quote/COLL/

https://www.collegiumpharma.com

https://sec.report/CIK/0001267565

Leadership team

Mr. Michael Thomas Heffernan B.S. Pharm, R.Ph. (Co-Founder & Chairman)